Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Filipits, M; Haddad, V; Schmid, K; Huynh, A; Dunant, A; André, F; Brambilla, E; Stahel, R; Pignon, JP; Soria, JC; Popper, HH; Le Chevalier, T; Pirker, R.
Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program.
Clin Cancer Res. 2007; 13(13): 3892-3898. [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Autor/innen der Med Uni Graz:
Popper Helmuth
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
PURPOSE: The purpose of our study was to determine whether multidrug resistance proteins (MRP) are of prognostic and/or predictive value in patients who were enrolled into the International Adjuvant Lung Cancer Trial (IALT). EXPERIMENTAL DESIGN: Expression of MRP1 and MRP2 was immunohistochemically assessed in tumor specimens obtained from 782 IALT patients. Prognostic and predictive analyses were based on Cox models adjusted for clinical and pathologic variables. RESULTS: MRP1 expression was considered positive in 364 (47%) patients and MRP2 expression in 313 (40%) patients. MRP2-positive patients had a significantly shorter overall survival than MRP2-negative patients in the total patient population [adjusted hazard ratio for death, 1.37; 95% confidence interval (95% CI), 1.09-1.72; P = 0.007]. There was no significant association between MRP1 expression and overall survival. Neither MRP1 nor MRP2 predicted response to adjuvant cisplatin-based chemotherapy. CONCLUSIONS: MRP2 expression is an independent prognostic factor in patients with completely resected non-small cell lung cancer but neither MRP1 nor MRP2 was of predictive value in patients enrolled into the IALT.
Find related publications in this database (using NLM MeSH Indexing)
Aged -
Carcinoma, Non-Small-Cell Lung - drug therapy
Chemotherapy, Adjuvant - methods
Drug Resistance, Multiple - methods
Drug Resistance, Neoplasm - methods
Female - methods
Gene Expression Regulation, Neoplastic - methods
Humans - methods
Lung Neoplasms - drug therapy
Male - drug therapy
Membrane Transport Proteins - biosynthesis
Middle Aged - biosynthesis
Multidrug Resistance-Associated Proteins - biosynthesis
Prognosis - biosynthesis
Retrospective Studies - biosynthesis

© Meduni Graz Impressum